Assessment of naltrexone antagonism of buprenorphine View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-02

AUTHORS

M. Escher, J. Chabert, Y. Daali, V. Piguet, P. Dayer, J. Desmeules

ABSTRACT

Buprenorphine (BUP), a semi-synthetic opioid, has unique pharmacologic characteristics: high affinity, slow dissociation constant, and prolonged duration of effect. The possibility of reversing its effects was questioned. Naltrexone (NTX), a pure opioid antagonist, has a higher receptor affinity than naloxone and blocks agonist-related effects for at least 24 hours. We assessed the efficacy of NTX in reversing the analgesic effects of BUP. Randomized double-blind placebo-controlled cross-over study including 12 healthy male volunteers. On three separate days they received either 0.15 mg/70 kg BUP iv followed 45 minutes later by 50 mg NTX po, or BUP followed by placebo (PBO), or PBO followed by NTX. Data were collected up to 8 hours after drug administration. Quantitative sensory testing using thermal and electrical stimulations (Viking IV, Madison USA) was performed. Pain tolerance (cold pressor test) was assessed. BUP markedly increased the nociceptive threshold (BUP-PBO 54% vs 13% PBO-NTX; p<0.05), and pain tolerance (BUP-PBO 50% vs PBO-NTX 2%; p<0.01). NTX reversed BUP antinociceptive effects (pain tolerance: 68.5% decrease of the AUC of BUP-NTX compared to the AUC of BUP-PBO; p=0.008). NTX shortened the duration of the antinociceptive effect (<6 h vs >8 h). Naltrexone reverses the antinociceptive effects of buprenorphine. The late reversal is probably due to delayed absorption. Clinical Pharmacology & Therapeutics (2005) 77, P9–P9; doi: 10.1016/j.clpt.2004.11.036 More... »

PAGES

p9-p9

Identifiers

URI

http://scigraph.springernature.com/pub.10.1016/j.clpt.2004.11.036

DOI

http://dx.doi.org/10.1016/j.clpt.2004.11.036

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1016932757


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Geneva University Hospitals Geneva Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.150338.c", 
          "name": [
            "Geneva University Hospitals Geneva Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escher", 
        "givenName": "M.", 
        "id": "sg:person.0623044674.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623044674.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Geneva University Hospitals Geneva Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.150338.c", 
          "name": [
            "Geneva University Hospitals Geneva Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chabert", 
        "givenName": "J.", 
        "id": "sg:person.0651776717.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651776717.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Geneva University Hospitals Geneva Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.150338.c", 
          "name": [
            "Geneva University Hospitals Geneva Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Daali", 
        "givenName": "Y.", 
        "id": "sg:person.01036100141.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036100141.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Geneva University Hospitals Geneva Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.150338.c", 
          "name": [
            "Geneva University Hospitals Geneva Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Piguet", 
        "givenName": "V.", 
        "id": "sg:person.01230322604.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230322604.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Geneva University Hospitals Geneva Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.150338.c", 
          "name": [
            "Geneva University Hospitals Geneva Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dayer", 
        "givenName": "P.", 
        "id": "sg:person.01236604437.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236604437.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Geneva University Hospitals Geneva Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.150338.c", 
          "name": [
            "Geneva University Hospitals Geneva Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Desmeules", 
        "givenName": "J.", 
        "id": "sg:person.01266555141.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266555141.71"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2005-02", 
    "datePublishedReg": "2005-02-01", 
    "description": "Buprenorphine (BUP), a semi-synthetic opioid, has unique pharmacologic characteristics: high affinity, slow dissociation constant, and prolonged duration of effect. The possibility of reversing its effects was questioned. Naltrexone (NTX), a pure opioid antagonist, has a higher receptor affinity than naloxone and blocks agonist-related effects for at least 24 hours. We assessed the efficacy of NTX in reversing the analgesic effects of BUP. Randomized double-blind placebo-controlled cross-over study including 12 healthy male volunteers. On three separate days they received either 0.15 mg/70 kg BUP iv followed 45 minutes later by 50 mg NTX po, or BUP followed by placebo (PBO), or PBO followed by NTX. Data were collected up to 8 hours after drug administration. Quantitative sensory testing using thermal and electrical stimulations (Viking IV, Madison USA) was performed. Pain tolerance (cold pressor test) was assessed. BUP markedly increased the nociceptive threshold (BUP-PBO 54% vs 13% PBO-NTX; p<0.05), and pain tolerance (BUP-PBO 50% vs PBO-NTX 2%; p<0.01). NTX reversed BUP antinociceptive effects (pain tolerance: 68.5% decrease of the AUC of BUP-NTX compared to the AUC of BUP-PBO; p=0.008). NTX shortened the duration of the antinociceptive effect (<6 h vs >8 h). Naltrexone reverses the antinociceptive effects of buprenorphine. The late reversal is probably due to delayed absorption. Clinical Pharmacology & Therapeutics (2005) 77, P9\u2013P9; doi: 10.1016/j.clpt.2004.11.036", 
    "genre": "article", 
    "id": "sg:pub.10.1016/j.clpt.2004.11.036", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1017409", 
        "issn": [
          "0009-9236", 
          "1532-6535"
        ], 
        "name": "Clinical Pharmacology & Therapeutics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "77"
      }
    ], 
    "keywords": [
      "antinociceptive effect", 
      "double-blind placebo-controlled cross-over study", 
      "placebo-controlled cross-over study", 
      "pain tolerance", 
      "cross-over study", 
      "unique pharmacologic characteristics", 
      "pure opioid antagonist", 
      "efficacy of naltrexone", 
      "quantitative sensory testing", 
      "duration of effect", 
      "healthy male volunteers", 
      "semi-synthetic opioid", 
      "high receptor affinity", 
      "naltrexone antagonism", 
      "analgesic effect", 
      "nociceptive threshold", 
      "opioid antagonist", 
      "pharmacologic characteristics", 
      "electrical stimulation", 
      "male volunteers", 
      "sensory testing", 
      "naltrexone", 
      "clinical pharmacology", 
      "buprenorphine", 
      "separate days", 
      "Drug Administration", 
      "placebo", 
      "receptor affinity", 
      "duration", 
      "late reversal", 
      "hours", 
      "high affinity", 
      "slow dissociation", 
      "naloxone", 
      "opioids", 
      "mg/70", 
      "antagonist", 
      "administration", 
      "volunteers", 
      "stimulation", 
      "efficacy", 
      "effect", 
      "pharmacology", 
      "antagonism", 
      "days", 
      "minutes", 
      "tolerance", 
      "assessment", 
      "affinity", 
      "testing", 
      "study", 
      "DOI", 
      "reversal", 
      "PO", 
      "threshold", 
      "data", 
      "possibility", 
      "characteristics", 
      "dissociation", 
      "absorption", 
      "agonist-related effects", 
      "BUP iv", 
      "NTX po", 
      "BUP antinociceptive effects", 
      "Therapeutics (2005) 77", 
      "P9\u2013P9"
    ], 
    "name": "Assessment of naltrexone antagonism of buprenorphine", 
    "pagination": "p9-p9", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1016932757"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1016/j.clpt.2004.11.036"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1016/j.clpt.2004.11.036", 
      "https://app.dimensions.ai/details/publication/pub.1016932757"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:17", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_408.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1016/j.clpt.2004.11.036"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1016/j.clpt.2004.11.036'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1016/j.clpt.2004.11.036'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1016/j.clpt.2004.11.036'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1016/j.clpt.2004.11.036'


 

This table displays all metadata directly associated to this object as RDF triples.

159 TRIPLES      21 PREDICATES      92 URIs      84 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1016/j.clpt.2004.11.036 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Na6c1fa2c9a40477ba316ce9fa00ced48
4 schema:datePublished 2005-02
5 schema:datePublishedReg 2005-02-01
6 schema:description Buprenorphine (BUP), a semi-synthetic opioid, has unique pharmacologic characteristics: high affinity, slow dissociation constant, and prolonged duration of effect. The possibility of reversing its effects was questioned. Naltrexone (NTX), a pure opioid antagonist, has a higher receptor affinity than naloxone and blocks agonist-related effects for at least 24 hours. We assessed the efficacy of NTX in reversing the analgesic effects of BUP. Randomized double-blind placebo-controlled cross-over study including 12 healthy male volunteers. On three separate days they received either 0.15 mg/70 kg BUP iv followed 45 minutes later by 50 mg NTX po, or BUP followed by placebo (PBO), or PBO followed by NTX. Data were collected up to 8 hours after drug administration. Quantitative sensory testing using thermal and electrical stimulations (Viking IV, Madison USA) was performed. Pain tolerance (cold pressor test) was assessed. BUP markedly increased the nociceptive threshold (BUP-PBO 54% vs 13% PBO-NTX; p<0.05), and pain tolerance (BUP-PBO 50% vs PBO-NTX 2%; p<0.01). NTX reversed BUP antinociceptive effects (pain tolerance: 68.5% decrease of the AUC of BUP-NTX compared to the AUC of BUP-PBO; p=0.008). NTX shortened the duration of the antinociceptive effect (<6 h vs >8 h). Naltrexone reverses the antinociceptive effects of buprenorphine. The late reversal is probably due to delayed absorption. Clinical Pharmacology & Therapeutics (2005) 77, P9–P9; doi: 10.1016/j.clpt.2004.11.036
7 schema:genre article
8 schema:inLanguage en
9 schema:isAccessibleForFree false
10 schema:isPartOf N5ba079de07d641209acbbb7cf040086c
11 N5f85928a451a47848d0eec589380f070
12 sg:journal.1017409
13 schema:keywords BUP antinociceptive effects
14 BUP iv
15 DOI
16 Drug Administration
17 NTX po
18 P9–P9
19 PO
20 Therapeutics (2005) 77
21 absorption
22 administration
23 affinity
24 agonist-related effects
25 analgesic effect
26 antagonism
27 antagonist
28 antinociceptive effect
29 assessment
30 buprenorphine
31 characteristics
32 clinical pharmacology
33 cross-over study
34 data
35 days
36 dissociation
37 double-blind placebo-controlled cross-over study
38 duration
39 duration of effect
40 effect
41 efficacy
42 efficacy of naltrexone
43 electrical stimulation
44 healthy male volunteers
45 high affinity
46 high receptor affinity
47 hours
48 late reversal
49 male volunteers
50 mg/70
51 minutes
52 naloxone
53 naltrexone
54 naltrexone antagonism
55 nociceptive threshold
56 opioid antagonist
57 opioids
58 pain tolerance
59 pharmacologic characteristics
60 pharmacology
61 placebo
62 placebo-controlled cross-over study
63 possibility
64 pure opioid antagonist
65 quantitative sensory testing
66 receptor affinity
67 reversal
68 semi-synthetic opioid
69 sensory testing
70 separate days
71 slow dissociation
72 stimulation
73 study
74 testing
75 threshold
76 tolerance
77 unique pharmacologic characteristics
78 volunteers
79 schema:name Assessment of naltrexone antagonism of buprenorphine
80 schema:pagination p9-p9
81 schema:productId N37a1d48017bc46b0b3785eb3103556a1
82 N76a846c1de994fa69e995b004d7bd3af
83 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016932757
84 https://doi.org/10.1016/j.clpt.2004.11.036
85 schema:sdDatePublished 2021-12-01T19:17
86 schema:sdLicense https://scigraph.springernature.com/explorer/license/
87 schema:sdPublisher N7b653233401e4ef0840c0a0726cee158
88 schema:url https://doi.org/10.1016/j.clpt.2004.11.036
89 sgo:license sg:explorer/license/
90 sgo:sdDataset articles
91 rdf:type schema:ScholarlyArticle
92 N37a1d48017bc46b0b3785eb3103556a1 schema:name doi
93 schema:value 10.1016/j.clpt.2004.11.036
94 rdf:type schema:PropertyValue
95 N592fdb3059ff4e788654f30080a07869 rdf:first sg:person.01236604437.19
96 rdf:rest Nbbf67824133648fb824174d95d7c0273
97 N5ba079de07d641209acbbb7cf040086c schema:issueNumber 2
98 rdf:type schema:PublicationIssue
99 N5f85928a451a47848d0eec589380f070 schema:volumeNumber 77
100 rdf:type schema:PublicationVolume
101 N76a846c1de994fa69e995b004d7bd3af schema:name dimensions_id
102 schema:value pub.1016932757
103 rdf:type schema:PropertyValue
104 N7b653233401e4ef0840c0a0726cee158 schema:name Springer Nature - SN SciGraph project
105 rdf:type schema:Organization
106 N8038420b84eb4841a16e796f8535ed9e rdf:first sg:person.0651776717.34
107 rdf:rest N9eb3e4140ae348f89601b4bf98704a30
108 N9eb3e4140ae348f89601b4bf98704a30 rdf:first sg:person.01036100141.24
109 rdf:rest Nc5ce0733db1b4e2698d07bb4eff90e69
110 Na6c1fa2c9a40477ba316ce9fa00ced48 rdf:first sg:person.0623044674.43
111 rdf:rest N8038420b84eb4841a16e796f8535ed9e
112 Nbbf67824133648fb824174d95d7c0273 rdf:first sg:person.01266555141.71
113 rdf:rest rdf:nil
114 Nc5ce0733db1b4e2698d07bb4eff90e69 rdf:first sg:person.01230322604.64
115 rdf:rest N592fdb3059ff4e788654f30080a07869
116 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
117 schema:name Medical and Health Sciences
118 rdf:type schema:DefinedTerm
119 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
120 schema:name Clinical Sciences
121 rdf:type schema:DefinedTerm
122 sg:journal.1017409 schema:issn 0009-9236
123 1532-6535
124 schema:name Clinical Pharmacology & Therapeutics
125 schema:publisher Springer Nature
126 rdf:type schema:Periodical
127 sg:person.01036100141.24 schema:affiliation grid-institutes:grid.150338.c
128 schema:familyName Daali
129 schema:givenName Y.
130 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036100141.24
131 rdf:type schema:Person
132 sg:person.01230322604.64 schema:affiliation grid-institutes:grid.150338.c
133 schema:familyName Piguet
134 schema:givenName V.
135 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230322604.64
136 rdf:type schema:Person
137 sg:person.01236604437.19 schema:affiliation grid-institutes:grid.150338.c
138 schema:familyName Dayer
139 schema:givenName P.
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236604437.19
141 rdf:type schema:Person
142 sg:person.01266555141.71 schema:affiliation grid-institutes:grid.150338.c
143 schema:familyName Desmeules
144 schema:givenName J.
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266555141.71
146 rdf:type schema:Person
147 sg:person.0623044674.43 schema:affiliation grid-institutes:grid.150338.c
148 schema:familyName Escher
149 schema:givenName M.
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623044674.43
151 rdf:type schema:Person
152 sg:person.0651776717.34 schema:affiliation grid-institutes:grid.150338.c
153 schema:familyName Chabert
154 schema:givenName J.
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651776717.34
156 rdf:type schema:Person
157 grid-institutes:grid.150338.c schema:alternateName Geneva University Hospitals Geneva Switzerland
158 schema:name Geneva University Hospitals Geneva Switzerland
159 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...